Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2014

Open Access 01-12-2014 | Research

Predictors of hospital surface contamination with Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: patient and organism factors

Authors: Joshua T Freeman, Jessica Nimmo, Eva Gregory, Audrey Tiong, Mary De Almeida, Gary N McAuliffe, Sally A Roberts

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2014

Login to get access

Abstract

Background

The role of the hospital environment in transmission of ESBL-Klebsiella pneumoniae (ESBL-KP) and ESBL-Escherichia coli (ESBL-EC) is poorly defined. Recent data however suggest that in the hospital setting, ESBL-KP is more transmissible than ESBL-EC. We sought therefore to measure the difference in hospital contamination rates between the two species and to identify key risk factors for contamination of the hospital environment with these organisms.

Methods

We systematically sampled 8 surfaces in the rooms and bathrooms of adult patients colonized or infected with ESBL-EC or ESBL-KP throughout their hospital stay. Data were collected on factors potentially affecting contamination rates. Environmental contamination was defined as recovery of an ESBL-producing organism matching the source patient’s isolate. Multivariate logistic regression analysis was performed at the level of the patient visit using generalized estimating equations to identify independent predictors of environmental contamination.

Results

24 patients (11 with ESBL-KP, 11 ESBL-EC and 2 with both organisms) had 1104 swabs collected during 138 visits. The overall contamination rate was 3.4% (38/1104) and was significantly higher for ESBL-KP than ESBL-EC (5.4% versus 0.4%; p < 0.0001). After multivariate analysis, environmental contamination was found to be negatively associated with carbapenem exposure (OR 0.06 [95% CI 0.01-0.61]; p = 0.017) and positively associated with the presence of an indwelling urinary catheter (OR 6.12 [95% CI 1.23-30.37]; p = 0.027) and ESBL-KP in the source patient (OR 26.23 [95% CI 2.70-254.67]; p = 0.005).

Conclusions

Contamination of the hospital environment with ESBL-producing Enterobacteriaceae (ESBL-E) is inversely associated with carbapenem exposure. Predictors of hospital contamination with ESBL-E include: indwelling urinary catheters and ESBL-KP. Rooms of patients with ESBL-KP have substantially higher contamination rates than those with ESBL-EC. This finding may help explain the apparently higher transmissibility of ESBL-KP in the hospital setting.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoban DJ, Bouchillon SK, Hawser SP, Badal RE: Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002–2007. Diagn Microbiol Infect Dis. 2010, 66: 78-86. 10.1016/j.diagmicrobio.2009.06.009.PubMedCrossRef Hoban DJ, Bouchillon SK, Hawser SP, Badal RE: Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002–2007. Diagn Microbiol Infect Dis. 2010, 66: 78-86. 10.1016/j.diagmicrobio.2009.06.009.PubMedCrossRef
2.
go back to reference Hawser SP, Badal RE, Bouchillon SK: Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010. Int J Antimicrob Agents. 2013, 41: 224-228. 10.1016/j.ijantimicag.2012.10.014.PubMedCrossRef Hawser SP, Badal RE, Bouchillon SK: Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010. Int J Antimicrob Agents. 2013, 41: 224-228. 10.1016/j.ijantimicag.2012.10.014.PubMedCrossRef
3.
go back to reference Oteo J, Navarro C, Cercenado E: Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long term care facilities and hospital institutions. J Clin Microbiol. 2006, 44: 2359-2366. 10.1128/JCM.00447-06.PubMedPubMedCentralCrossRef Oteo J, Navarro C, Cercenado E: Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long term care facilities and hospital institutions. J Clin Microbiol. 2006, 44: 2359-2366. 10.1128/JCM.00447-06.PubMedPubMedCentralCrossRef
4.
go back to reference Rodriguez-Bano J, Picon E, Gijo P: Community-onset bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010, 50: 40-48. 10.1086/649537.PubMedCrossRef Rodriguez-Bano J, Picon E, Gijo P: Community-onset bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010, 50: 40-48. 10.1086/649537.PubMedCrossRef
5.
go back to reference Siegel JD, Rhinehart E, Jackson M, Chiarello L: Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control. 2007, 35S: 165-193.CrossRef Siegel JD, Rhinehart E, Jackson M, Chiarello L: Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control. 2007, 35S: 165-193.CrossRef
6.
go back to reference Freeman JT, Williamson DA, Anderson DJ: When should contact precautions and active surveillance be used to manage patients with multidrug-resistant Enterobacteriaceae?. Infect Control Hosp Epidemiol. 2012, 33: 753-756. 10.1086/666333.PubMedCrossRef Freeman JT, Williamson DA, Anderson DJ: When should contact precautions and active surveillance be used to manage patients with multidrug-resistant Enterobacteriaceae?. Infect Control Hosp Epidemiol. 2012, 33: 753-756. 10.1086/666333.PubMedCrossRef
7.
go back to reference Nseir S, Blazejewski C, Lubret R, Wallet F, Courcol R, Durocher A: Risk of acquiring multidrug-resistant gram-negative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect. 2011, 17: 1201-1208. 10.1111/j.1469-0691.2010.03420.x.PubMedCrossRef Nseir S, Blazejewski C, Lubret R, Wallet F, Courcol R, Durocher A: Risk of acquiring multidrug-resistant gram-negative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect. 2011, 17: 1201-1208. 10.1111/j.1469-0691.2010.03420.x.PubMedCrossRef
8.
go back to reference Weber DJ, Rutala WA: Understanding and preventing transmission of healthcare-associated pathogens due to the contaminated hospital environment. Infect Control Hosp Epidemiol. 2013, 34: 449-452. 10.1086/670223.PubMedCrossRef Weber DJ, Rutala WA: Understanding and preventing transmission of healthcare-associated pathogens due to the contaminated hospital environment. Infect Control Hosp Epidemiol. 2013, 34: 449-452. 10.1086/670223.PubMedCrossRef
9.
go back to reference Adebola OA, Johnson JK, Harris AD: Risk of acquiring extended-spectrum β-lactamase-producing Klebsiella species and Escherichia coli from prior room occupants in the intensive care unit. Infect Control Hosp Epidemiol. 2013, 34: 453-458. 10.1086/670216.CrossRef Adebola OA, Johnson JK, Harris AD: Risk of acquiring extended-spectrum β-lactamase-producing Klebsiella species and Escherichia coli from prior room occupants in the intensive care unit. Infect Control Hosp Epidemiol. 2013, 34: 453-458. 10.1086/670216.CrossRef
10.
go back to reference Hilty M, Betsch BY, Bogli-Stuber K: Transmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis. 2012, 55: 967-975. 10.1093/cid/cis581.PubMedPubMedCentralCrossRef Hilty M, Betsch BY, Bogli-Stuber K: Transmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis. 2012, 55: 967-975. 10.1093/cid/cis581.PubMedPubMedCentralCrossRef
11.
go back to reference Harris AD, Kotetishvili M, Shurland S: How important is patient to patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am J Infect Control. 2007, 35: 97-101. 10.1016/j.ajic.2006.09.011.PubMedCrossRef Harris AD, Kotetishvili M, Shurland S: How important is patient to patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am J Infect Control. 2007, 35: 97-101. 10.1016/j.ajic.2006.09.011.PubMedCrossRef
12.
go back to reference Harris AD, Perencevich EN, Johnson JK: Patient to patient transmission is important in extended-spectrum β-lactamase producing Klebsiella pneumoniae acquisition. Clin Infect Dis. 2007, 45: 1347-1350. 10.1086/522657.PubMedCrossRef Harris AD, Perencevich EN, Johnson JK: Patient to patient transmission is important in extended-spectrum β-lactamase producing Klebsiella pneumoniae acquisition. Clin Infect Dis. 2007, 45: 1347-1350. 10.1086/522657.PubMedCrossRef
13.
go back to reference Cholley P, Thouverez M, Gbaguidi-Haore H: Hospital cross-transmission of extended-spectrum β-lactamase Escherichia coli and Klebsiella pneumoniae. Med Mal Infect. 2013, 43: 331-336. 10.1016/j.medmal.2013.06.001.PubMedCrossRef Cholley P, Thouverez M, Gbaguidi-Haore H: Hospital cross-transmission of extended-spectrum β-lactamase Escherichia coli and Klebsiella pneumoniae. Med Mal Infect. 2013, 43: 331-336. 10.1016/j.medmal.2013.06.001.PubMedCrossRef
14.
go back to reference McGregor JC, Kim PW, Perencevich EN: Utility of the chronic disease score and charlson comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005, 161: 483-493. 10.1093/aje/kwi068.PubMedCrossRef McGregor JC, Kim PW, Perencevich EN: Utility of the chronic disease score and charlson comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005, 161: 483-493. 10.1093/aje/kwi068.PubMedCrossRef
15.
go back to reference Kramer A, Schwebke I, Kampf G: How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis. 2006, 6: 130-10.1186/1471-2334-6-130.PubMedPubMedCentralCrossRef Kramer A, Schwebke I, Kampf G: How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis. 2006, 6: 130-10.1186/1471-2334-6-130.PubMedPubMedCentralCrossRef
16.
go back to reference Neely AN: A survey of gram negative bacteria survival on hospital fabrics and plastics. J Burn Care Rehabil. 2000, 21: 523-527. 10.1097/00004630-200021060-00009.PubMedCrossRef Neely AN: A survey of gram negative bacteria survival on hospital fabrics and plastics. J Burn Care Rehabil. 2000, 21: 523-527. 10.1097/00004630-200021060-00009.PubMedCrossRef
17.
go back to reference Guet-Rivellet H, Le Monnier A, Bretton N: Environmental contamination with extended-spectrum β-lactamases: is there any difference between Escherichia coli and klebsiella spp?. Am J Infect Control. 2012, 40: 845-848. 10.1016/j.ajic.2011.10.007.CrossRef Guet-Rivellet H, Le Monnier A, Bretton N: Environmental contamination with extended-spectrum β-lactamases: is there any difference between Escherichia coli and klebsiella spp?. Am J Infect Control. 2012, 40: 845-848. 10.1016/j.ajic.2011.10.007.CrossRef
18.
go back to reference Gbaguidi-Haore H, Talon D, Hocquet D, Bertrand X: Hospital environmental contamination with Enterobacteriaceae producing extended-spectrum β-lactamase. Am J Infect Control. 2013, 41: 664-665.PubMedCrossRef Gbaguidi-Haore H, Talon D, Hocquet D, Bertrand X: Hospital environmental contamination with Enterobacteriaceae producing extended-spectrum β-lactamase. Am J Infect Control. 2013, 41: 664-665.PubMedCrossRef
19.
go back to reference Meddings J, Rogers MA, Macy M, Saint S: Systematic review and meta-analysis: reminder systems to reduce catheter-associated urinary tract infections and urinary catheter use in hospitalized patients. Clin Infect Dis. 2010, 51: 550-560. 10.1086/655133.PubMedCrossRef Meddings J, Rogers MA, Macy M, Saint S: Systematic review and meta-analysis: reminder systems to reduce catheter-associated urinary tract infections and urinary catheter use in hospitalized patients. Clin Infect Dis. 2010, 51: 550-560. 10.1086/655133.PubMedCrossRef
20.
go back to reference Ben Ami R, Schwaber MJ, Nanon-Venezia S: Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis. 2006, 42: 925-934. 10.1086/500936.PubMedCrossRef Ben Ami R, Schwaber MJ, Nanon-Venezia S: Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis. 2006, 42: 925-934. 10.1086/500936.PubMedCrossRef
21.
go back to reference Hayakawa K, Gattu S, Marchaim D: Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large US medical center. Antimicrob Agents Chemother. 2013, 57: 4010-4018. 10.1128/AAC.02516-12.PubMedPubMedCentralCrossRef Hayakawa K, Gattu S, Marchaim D: Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large US medical center. Antimicrob Agents Chemother. 2013, 57: 4010-4018. 10.1128/AAC.02516-12.PubMedPubMedCentralCrossRef
22.
go back to reference Kang CI, Wi YM, Lee MY: Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012, 50: 312-317. 10.1128/JCM.06002-11.PubMedPubMedCentralCrossRef Kang CI, Wi YM, Lee MY: Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012, 50: 312-317. 10.1128/JCM.06002-11.PubMedPubMedCentralCrossRef
23.
go back to reference Donskey CJ, Chowdhry TK, Hecker MT: Effect of antibiotic therapy on the density of vancomycin resistant enterococci in the stool of colonized patients. N Engl J Med. 2000, 343: 1925-1932. 10.1056/NEJM200012283432604.PubMedPubMedCentralCrossRef Donskey CJ, Chowdhry TK, Hecker MT: Effect of antibiotic therapy on the density of vancomycin resistant enterococci in the stool of colonized patients. N Engl J Med. 2000, 343: 1925-1932. 10.1056/NEJM200012283432604.PubMedPubMedCentralCrossRef
24.
go back to reference Moore G, Muzslav M, Wilson PR: The type, level and distribution of microorganisms within the ward environment: a zonal analysis of an intensive care unit and gastrointestinal surgical ward. Infect Control Hosp Epidemiol. 2013, 34: 500-506. 10.1086/670219.PubMedCrossRef Moore G, Muzslav M, Wilson PR: The type, level and distribution of microorganisms within the ward environment: a zonal analysis of an intensive care unit and gastrointestinal surgical ward. Infect Control Hosp Epidemiol. 2013, 34: 500-506. 10.1086/670219.PubMedCrossRef
25.
go back to reference Judge C, Galvin S, Burke L, Thomas T, Humphreys H, Fitzgerald-Hughes D: Search and you will find: detecting extended-spectrum β-lactamase producing Klebsiella pneumoniae from a patient’s immediate environment. Infect Control Hosp Epidemiol. 2013, 34: 534-536. 10.1086/670206.PubMedCrossRef Judge C, Galvin S, Burke L, Thomas T, Humphreys H, Fitzgerald-Hughes D: Search and you will find: detecting extended-spectrum β-lactamase producing Klebsiella pneumoniae from a patient’s immediate environment. Infect Control Hosp Epidemiol. 2013, 34: 534-536. 10.1086/670206.PubMedCrossRef
Metadata
Title
Predictors of hospital surface contamination with Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: patient and organism factors
Authors
Joshua T Freeman
Jessica Nimmo
Eva Gregory
Audrey Tiong
Mary De Almeida
Gary N McAuliffe
Sally A Roberts
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2014
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/2047-2994-3-5

Other articles of this Issue 1/2014

Antimicrobial Resistance & Infection Control 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.